Bausch Health Companies (BHC) Income towards Parent Company (2009 - 2026)
Bausch Health Companies (BHC) reported Income towards Parent Company of -$1.4 billion for Q1 2026, down 1563.95% on a YoY basis from $97.7 million in Q1 2025, and down 1289.32% sequentially from -$103.0 million in Q4 2025.
Bausch Health Companies (BHC) Income towards Parent Company (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Income towards Parent Company data on file, last reported at -$1.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 1563.95% year-over-year to -$1.4 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 1412.35% YoY), and the FY2025 full-year result was $120.0 million, up 266.67% from the prior year.
- Income towards Parent Company slipped to -$1.4 billion in Q1 2026, from -$103.0 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $403.0 million in Q3 2022 to a low of -$1.4 billion in Q1 2026.
- A 5-year average of -$129.8 million and a median of -$77.0 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company soared 12900.0% in 2025 and plunged 1563.95% in 2026, its largest moves.
- Tracing BHC's Income towards Parent Company over 5 years: stood at -$410.0 million in 2022, then surged by 88.54% to -$47.0 million in 2023, then soared by 308.51% to $98.0 million in 2024, then slumped by 205.1% to -$103.0 million in 2025, then plunged by 1289.32% to -$1.4 billion in 2026.
- Business Quant data shows BHC's Income towards Parent Company at -$1.4 billion in Q1 2026, -$103.0 million in Q4 2025, and $181.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Bausch Health Companies | 1.68 Bn | 367.46 Mn | 2.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Bn |
| Dec 31, 2025 | -103.00 Mn |
| Sep 30, 2025 | 181.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Mar 31, 2025 | -86.00 Mn |
| Dec 31, 2024 | 98.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | -77.00 Mn |
| Dec 31, 2023 | -47.00 Mn |
| Sep 30, 2023 | -382.00 Mn |
| Jun 30, 2023 | 27.00 Mn |
| Mar 31, 2023 | -209.00 Mn |
| Dec 31, 2022 | -410.00 Mn |
| Sep 30, 2022 | 403.00 Mn |
| Jun 30, 2022 | -139.00 Mn |
| Mar 31, 2022 | -66.00 Mn |
| Dec 31, 2021 | 72.00 Mn |
| Sep 30, 2021 | 191.00 Mn |
| Jun 30, 2021 | -593.00 Mn |